

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CAL-51

RRID:CVCL_1110

Type: Cell Line

Proper Citation

RRID:CVCL_1110

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1110

Proper Citation: RRID:CVCL_1110

Sex: Female

Defining Citation: [PMID:2390488](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:12661003](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23122841](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25984343](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34339474](#), [PMID:35839778](#)

Comments: Derived from metastatic site: Pleural effusion., Misspelling: Ca151; In Cosmic 1057761., Omics: Transcriptome analysis., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep RNAseq analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Microsatellite instability: Unstable (MSI-low) (PubMed=12661003; PubMed=15677628; PubMed=31068700; Sanger)., Doubling time: 24 hours (PubMed=25984343); ~30 hours (PubMed=34339474); ~50-60 hours (DSMZ)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: GrayJW breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Name: CAL-51

Synonyms: CAL 51, CAL51, Cal51, Centre Antoine Lacassagne-51

Cross References: BTO:BTO:0000945, CLO:CLO_0002185, EFO:EFO_0005358, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473159, BioSample:SAMN10988576, Cell_Model_Passport:SIDM00933, ChEMBL-Cells:ChEMBL3308717, ChEMBL-Targets:ChEMBL1075411, Cosmic:687467, Cosmic:910927, Cosmic:1057761, Cosmic:2164986, Cosmic-CLP:910927, DepMap:ACH-000856, DSMZ:ACC-302, DSMZCellDive:ACC-302, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:910927, GEO:GSM115099, GEO:GSM217567, GEO:GSM274645, GEO:GSM274646, GEO:GSM344362, GEO:GSM344412, GEO:GSM350521, GEO:GSM459702, GEO:GSM783973, GEO:GSM827162, GEO:GSM847246, GEO:GSM847456, GEO:GSM886909, GEO:GSM887975, GEO:GSM1172946, GEO:GSM1374429, GEO:GSM1664565, GEO:GSM1669652, IARC_TP53:21211, IGRhCellID:CAL51, LiGeA:CCL_143, LINCS_HMS:50008, LINCS_LDP:LCL-1472, Lonza:1002, PharmacDB:CAL51_172_2019, PRIDE:PXD000953, PRIDE:PXD030304, Progenetix:CVCL_1110, PubChem_Cell_line:CVCL_1110, SLKBase:3399, Wikidata:Q54808406

ID: CVCL_1110

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260905T174513+0000

Ratings and Alerts

No rating or validation information has been found for CAL-51.

No alerts have been found for CAL-51.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tong J, et al. (2026) p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. Redox biology, 90, 104043.

Zhao Z, et al. (2026) Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 axis disrupts metabolic-epigenetic crosstalk and suppresses progression in hyperglycolytic breast cancer. Cancer letters, 644, 218328.

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. Molecular cancer, 25(1).

Bloomfield M, et al. (2026) Cell and Nuclear Size Is Associated with Chromosomal Instability and Tumorigenicity in Cancer Cells That Undergo Whole Genome Doubling. *Cancer research*, 86(9), 2126.

Heffner CM, et al. (2026) The ALS- and FTD-associated proteins annexin A11 and CHMP2B act sequentially in plasma membrane repair. *Developmental cell*, 61(7), 1487.

Hai LY, et al. (2026) HSPA6 Promotes Ferroptosis in Triple-Negative Breast Cancer by Rewiring Lipid Metabolism to Potentiate Membrane Lipid Peroxidation. *International journal of biological sciences*, 22(8), 4168.

Chen YC, et al. (2025) Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells. *eLife*, 13.

Chenoweth AM, et al. (2025) An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. *Cancer research*, 85(22), 4521.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Liao Q, et al. (2025) p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis. *Molecular cell*, 85(1), 132.

Xu W, et al. (2025) LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. *Molecular cancer research : MCR*, 23(10), 859.

Fowler CE, et al. (2025) The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing. *iScience*, 28(7), 112965.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Wang M, et al. (2024) Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates. *Cell chemical biology*, 31(12), 2039.

Zerbib J, et al. (2024) Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. *Nature communications*, 15(1), 7772.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(15), 3298.

Tran DH, et al. (2024) De novo and salvage purine synthesis pathways across tissues and tumors. *Cell*, 187(14), 3602.

Liu CC, et al. (2024) Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. *Cell reports. Medicine*, 5(2), 101396.

Zhang S, et al. (2024) NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells. *The FEBS journal*.

Chappidi N, et al. (2024) PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends. *Cell*, 187(4), 945.